Highlights Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Delayed Nasdaq Other stock markets 03:35:44 2024-05-02 pm EDT			5-day change	1st Jan Change
2.91 ^USD	-2.02%		-5.21%	-10.87%

Apr. 24	Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287	CI
Apr. 08	Gain Therapeutics Names Gene Mack as CFO	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287	Apr. 24	CI
Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer	Apr. 08	CI
Gain Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model	Dec. 01	CI
Gain Therapeutics Closes $10.1 Million Public Offering, Private Placement of Shares, Warrants	Nov. 24	MT
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson?s Disease	23-10-04	CI
Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model	23-08-28	CI
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Gain Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (GANX) GAIN THERAPEUTICS Posts Q1 Revenue $55,180	23-05-12	MT
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer	23-04-12	GL
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer	23-04-12	AQ
GAIN THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-23	AQ
GAIN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-10	AQ
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Gain Therapeutics, Inc. Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons	22-09-26	CI
Gain Therapeutics, Inc. Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease	22-09-19	CI
GAIN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-08	AQ
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Highlights

Filters